Defining the Role of Icosapent Ethyl in Clinical Practice. [Review]
Citation: American Journal of Cardiovascular Drugs. 20(6):517-524, 2020 Dec.PMID: 32157567Institution: MedStar Union Memorial HospitalForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Eicosapentaenoic Acid/aa [Analogs & Derivatives] | *Hypertriglyceridemia/dt [Drug Therapy] | Drug Dosage Calculations | Eicosapentaenoic Acid/ad [Administration & Dosage] | Eicosapentaenoic Acid/ae [Adverse Effects] | Eicosapentaenoic Acid/tu [Therapeutic Use] | Humans | Randomized Controlled Trials as Topic | Risk FactorsYear: 2020Local holdings: Available online from MWHC library: 2001 - 2009ISSN:- 1175-3277
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 32157567 | Available | 32157567 |
Available online from MWHC library: 2001 - 2009
The health benefit of fish oil, i.e. omega-3 fatty acids (omega-3 FA) has a long history of debate. While there are a number of medications to reduce serum triglyceride levels, none have shown unanimous cardiovascular (CV) benefits. The most recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) assessing the CV outcome of one highly purified prescription omega-3 FA has certainly rejuvenated the debate. While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT.
English